Expertise in
2
conditions

Dr. Thomas Julian

General Surgery
Allegheny General Hospital
320 E North Ave, 
Pittsburgh, PA 
Expertise in
2
conditions
Allegheny General Hospital
320 E North Ave, 
Pittsburgh, PA 

Overview

Thomas Julian is a General Surgeon practicing medicine in Pittsburgh, Pennsylvania.

Dr. Julian is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Lymphedema, Angiosarcoma, Menopause, and Mastectomy.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 9 clinical trials.

Specialties

General Surgery

Licenses

Surgery in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UPMC
  • EPO
  • PPO

Locations

Allegheny General Hospital
320 E North Ave, Pittsburgh, PA 15212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
NSABP Biospecimen Discovery Project
NSABP Biospecimen Discovery Project
Enrollment Status: Unknown
Publish Date: October 05, 2021
Intervention Type: Biological, Drug
View 8 Less Clinical Trials

53 Total Publications

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
Journal: Future oncology (London, England)
Published: June 27, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Thomas Gleason
General Surgery
Expertise in
22
conditions
Dr. Thomas Gleason
General Surgery

Upmc

5200 Centre Ave Ste 715, 
Pittsburgh, PA 
 (3.8 miles away)
412-623-3140
Languages Spoken:
English
See accepted insurances

Thomas Gleason is a General Surgeon practicing medicine in Pittsburgh, Pennsylvania. Dr. Gleason is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Aortic Dissection, Aortic Valve Stenosis, Thoracic Aortic Aneurysm, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

Expertise in
24
conditions
Dr. Ian Pollack
General Surgery
Expertise in
24
conditions
Dr. Ian Pollack
General Surgery

UPMC Children's Hospital Of Pittsburgh, Pediatric Neurological Surgery

4401 Penn Avenue, 
Pittsburgh, PA 
 (2.7 miles away)
412-336-3075
Languages Spoken:
English
See accepted insurances

Ian Pollack, MD, is Chief of Pediatric Neurosurgery at UPMC Children’s Hospital of Pittsburgh, A. Leland Albright Professor of Neurosurgery, and vice-chair for Academic Affairs at the University of Pittsburgh School of Medicine. He is professor of clinical and translational science and distinguished professor of neurosurgery at the University of Pittsburgh. Dr. Pollack is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Decompression, and Craniectomy. Dr. Pollack is board certified in American Board Of Neurological Surgery.

Expertise in
12
conditions
Dr. Blair Jobe
General Surgery
Expertise in
12
conditions
Dr. Blair Jobe
General Surgery

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (0.1 miles away)
412-359-6137
Languages Spoken:
English
See accepted insurances

Blair Jobe is a General Surgeon practicing medicine in Pittsburgh, Pennsylvania. Dr. Jobe is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Barrett Esophagus, Hiatal Hernia, Endoscopy, and Gastrostomy.

Frequently Asked Questions about Dr. Thomas Julian

How do I make an appointment with Dr. Thomas Julian?

You can book an appointment with Dr. Thomas Julian by calling their office at 412-359-8229. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas Julian a top-rated expert for Mastectomy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas Julian is classified as an Elite expert for Mastectomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas Julian specialize in?

While Dr. Thomas Julian is a General Surgery, they have specific expertise in Mastectomy, Breast Cancer, and Lymphedema. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Thomas Julian participate in research or clinical trials?

Yes. Dr. Thomas Julian has published 53 articles and abstracts on conditions like Mastectomy. You can view a list of Dr. Thomas Julian's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas Julian accept my insurance?

Dr. Thomas Julian accepts most major insurance plans, including UPMC. We recommend calling the office directly at 412-359-8229 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Julian's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile